Stock Market Reviews

NRIX (Nurix Therapeutics, Inc.) News

Get the latest news, insights, and market updates on NRIX (Nurix Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
  Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ
  Nov 10, 2025 - $NRIX
• Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
  Data are being presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual MeetingSAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CB
  Nov 7, 2025 - $NRIX
• What Nurix Therapeutics (NRIX)'s Phase 2 NX-5948 Trial Launch Means For Shareholders
  Nurix Therapeutics recently announced the initiation of the pivotal Phase 2 DAYBreak trial of its BTK degrader candidate NX-5948 in relapsed or refractory chronic lymphocytic leukemia, alongside plans to present new clinical data at the upcoming American Society of Hematology Annual Meeting in December 2025. These advances underscore the company’s momentum in targeted protein degradation and suggest growing interest in their approach from both the scientific and investment communities. We'll...
  Nov 5, 2025 - $NRIX
• Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
  SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December
  Nov 3, 2025 - $NRIX
• Nurix Therapeutics to Participate in Upcoming Investor Conferences
  SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences in November. Stifel 2025 Healthcare Conference, New York, NY Thursday, November 13, 2025, fr
  Oct 30, 2025 - $NRIX
• Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
  SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the offering were $250.0
  Oct 27, 2025 - $NRIX
• Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed
  Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 14, H.C. Wainwright lowered its price target on Nurix Therapeutics (NASDAQ:NRIX) from $34.00 to $33.00, while reaffirming its Buy rating after the company’s Q3 2025 earnings. Nurix reported a net loss of $1.03 per share, wider […]
  Oct 26, 2025 - $NRIX
• Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
  SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share. The gross proceeds to Nurix from the offering, before deducting underwriting discounts a
  Oct 22, 2025 - $NRIX
• Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
  600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a cl
  Oct 22, 2025 - $NRIX
• Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
  NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in tumor biomarkers, tumor shrinkage, long-term stable disease, and a confirmed partial response in heavily pretreated patients Data support initiation of expansion cohorts at the two highest doses tested as monotherapy or combinatio
  Oct 18, 2025 - $NRIX